News
04-26-2011, 04:20 AM
Today, Merck announced that Health Canada has extended the indication of GARDASIL in women up to the age of 45. Merck's HPV vaccine is now approved for girls and women nine through 45 years of age for the prevention of cervical cancer, vulvar and vaginal cancers, precancerous lesions and genital warts caused by the Human Papillomavirus types 6, 11, 16, 18. Previously, GARDASIL was approved in girls and women nine through 26.
More... (http://www.news-medical.net/news/20110426/Merck-receives-Health-Canada-approval-for-GARDASIL-to-treat-HPV-in-women-upto-age-45.aspx)
More... (http://www.news-medical.net/news/20110426/Merck-receives-Health-Canada-approval-for-GARDASIL-to-treat-HPV-in-women-upto-age-45.aspx)